Interleukin-7 or interleukin-15 enhances survival of Mycobacterium tuberculosis-infected mice.
about
The role of interleukin-15 in inflammation and immune responses to infection: implications for its therapeutic usePersistent high mortality in advanced HIV/TB despite appropriate antiretroviral and antitubercular therapy: an emerging challengeGene expression profiling identifies MMP-12 and ADAMDEC1 as potential pathogenic mediators of pulmonary sarcoidosis.Diminished plasma levels of common γ-chain cytokines in pulmonary tuberculosis and reversal following treatmentAdjuvant IL-7 or IL-15 overcomes immunodominance and improves survival of the CD8+ memory cell pool.Combined IL-15/IL-15Ralpha immunotherapy maximizes IL-15 activity in vivo.Induction of Mycobacterium tuberculosis-specific primary and secondary T-cell responses in interleukin-15-deficient mice.Aberrant plasma IL-7 and soluble IL-7 receptor levels indicate impaired T-cell response to IL-7 in human tuberculosis.Human macrophage activation programs induced by bacterial pathogens.Interleukin-2 and loss of immunity in experimental Mycobacterium avium infectionIL-15 prevents apoptosis, reverses innate and adaptive immune dysfunction, and improves survival in sepsis.Codelivery of IL-7 Augments Multigenic HCV DNA Vaccine-induced Antibody as well as Broad T Cell Responses in Cynomolgus MonkeysThe tuberculosis vaccine candidate Bacillus Calmette-Guérin ΔureC::hly coexpressing human interleukin-7 or -18 enhances antigen-specific T cell responses in miceDNA vaccines against human immunodeficiency virus type 1 in the past decade.Interleukin-7 produced by intestinal epithelial cells in response to Citrobacter rodentium infection plays a major role in innate immunity against this pathogen.IL-15 Superagonist Expands mCD8+ T, NK and NKT Cells after Burn Injury but Fails to Improve Outcome during Burn Wound InfectionRapid down-regulation of γc on T cells in early SIV infection correlates with impairment of T-cell function.Host Immune Responses Differ between M. africanum- and M. tuberculosis-Infected Patients following Standard Anti-tuberculosis Treatment.Interleukin-15 as an immune adjuvant to increase the efficacy of Mycobacterium bovis bacillus Calmette-Guérin vaccination.Prime-boost vaccination with rBCG/rAd35 enhances CD8⁺ cytolytic T-cell responses in lesions from Mycobacterium tuberculosis-infected primates.The influence of age on immunity to infection with Mycobacterium tuberculosis.Translational mini-review series on vaccines: Development and evaluation of improved vaccines against tuberculosis.IL-7 and IL-15 differentially regulate CD8+ T-cell subsets during contraction of the immune response.Adjunct immunotherapies for tuberculosis.The BCG replacement vaccine VPM1002: from drawing board to clinical trial.Inflammation and tuberculosis: host-directed therapies.Mathematical model reveals how regulating the three phases of T-cell response could counteract immune evasion.MHC class II tetramer guided detection of Mycobacterium tuberculosis-specific CD4+ T cells in peripheral blood from patients with pulmonary tuberculosis.IL-15 protects antigen-specific CD8+ T cell contraction after Mycobacterium bovis bacillus Calmette-Guérin infection.Next-Generation Vaccines Based on Bacille Calmette-Guérin.Th1 cytokines, true functional signatures for protective immunity against TB?Increased (6 exon) interleukin-7 production after M. tuberculosis infection and soluble interleukin-7 receptor expression in lung tissue
P2860
Q24599103-4ED4FFCA-FDE1-41C0-A5B2-14530D186F40Q28088557-9C661392-E8C2-4187-8736-94368A417F54Q30487702-7FAA5435-CDAC-4877-A125-2DCF2E07AB44Q33610319-B0BA1906-33AA-434B-9347-D258408E24E7Q33736534-F3CAC0DD-4890-414E-BDA0-4F21C260064EQ33760403-2A9F1ABD-71B7-484E-A4A5-A5651C6CCA79Q33769144-278D688E-CFDB-49E8-B008-BD761B25EA1BQ33803416-D4C7EB79-7F4A-4A86-B81B-0E3BD4840012Q34009967-37FEBB7E-E90C-4432-8BEF-44B6D497ACCCQ34115948-DDF7AD5E-6F91-4434-BE28-9BB95AD17618Q34120958-DE62133D-0B73-42FF-AE6F-AE7ED1BB8E98Q34521022-AC422D73-531B-49F2-A3B4-9B484A8DD9B5Q35043659-33263B6D-FEF5-4942-AABB-FF4111C32462Q35745831-88664753-46B8-409D-B8A6-9569A0057BCCQ35833835-3BE68FC8-CCB2-4D6D-9011-A28151F57327Q35918321-D5646268-D916-47EA-BD67-3E7C0C570579Q35987907-A7D5F303-75F4-476A-BC83-2D273F0B6F23Q36021134-0D4C65D5-2F30-4B96-BCAB-067557E5A070Q36044987-BA833255-A687-44EC-B01E-F1B49B06A193Q36071705-48C0A3CC-B068-4CE2-92B4-DF9EF8C5D3F1Q36121063-7B91FBAE-27F3-4F9F-AE25-77CED75F254DQ36736465-8DAE321B-4E48-479B-9E3A-84776F91D7A7Q36948598-F1E359AE-698C-4AAD-A160-0B821F7EB8C8Q37998000-3885B641-7369-44BE-9E7D-AA1E2753D63EQ38202181-590DBFEC-749D-44C2-B9FF-4E1FCD61CF70Q38203352-2BA420A1-A2F4-4CCB-8537-97276E5EDDDFQ38990485-E2815985-2106-4B8F-B818-D130CD5802AAQ42617680-F15FC0C1-EAEB-440E-B58F-9F8DF1E6B6FEQ47953672-76D2B303-C1C6-440F-9995-AB5AF0F81796Q49829375-DA2840C9-E094-42F7-A06D-3F6ADFFD1E07Q49900955-2CAAD9FF-76A1-4397-84EE-70A9DCB8B2E6Q57209222-087AF306-501D-4F61-BF45-DA9559167CD8
P2860
Interleukin-7 or interleukin-15 enhances survival of Mycobacterium tuberculosis-infected mice.
description
2000 nî lūn-bûn
@nan
2000 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2000 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2000年の論文
@ja
2000年論文
@yue
2000年論文
@zh-hant
2000年論文
@zh-hk
2000年論文
@zh-mo
2000年論文
@zh-tw
2000年论文
@wuu
name
Interleukin-7 or interleukin-1 ...... um tuberculosis-infected mice.
@ast
Interleukin-7 or interleukin-1 ...... um tuberculosis-infected mice.
@en
Interleukin-7 or interleukin-1 ...... um tuberculosis-infected mice.
@nl
type
label
Interleukin-7 or interleukin-1 ...... um tuberculosis-infected mice.
@ast
Interleukin-7 or interleukin-1 ...... um tuberculosis-infected mice.
@en
Interleukin-7 or interleukin-1 ...... um tuberculosis-infected mice.
@nl
prefLabel
Interleukin-7 or interleukin-1 ...... um tuberculosis-infected mice.
@ast
Interleukin-7 or interleukin-1 ...... um tuberculosis-infected mice.
@en
Interleukin-7 or interleukin-1 ...... um tuberculosis-infected mice.
@nl
P2093
P2860
P1476
Interleukin-7 or interleukin-1 ...... um tuberculosis-infected mice.
@en
P2093
M J Maeurer
P2860
P304
P356
10.1128/IAI.68.5.2962-2970.2000
P407
P577
2000-05-01T00:00:00Z